Introduction
In the past few years, more than 100 clinical trials have been initiated to evaluate the potential of gene therapy to cure genetic diseases, cancer, AIDS and several other diseases in man. In most such trials, genes have been introduced into the patient's cells ex vivo using retroviral vector technology, followed by the re-injection of the selected, gene-transduced cells into the patient. Although very promising results had been obtained in small animal model systems, there are no reports which show that one or the other protocol led to the complete cure of a disease in humans. However, no negative effect or complications after such treatments have been described.
In most clinical trials, genes have been transduced using retroviral vectors derived from amphotropic (ampho) murine leukemia virus (MLV). In contrast to ecotropic (eco) MLV, which only infects mouse cells, ampho-MLV has a very broad host range and can infect various tissues of many species including humans. This also applies to ampho-MLV-derived retroviral vectors. 1 Due to this broad host range and due to the relatively low level of gene transduction efficiency, gene therapy protocols have to be performed ex vivo. If injected directly into the blood stream, the chances that the vector particles would infect their actual target cells are extremely low. Furthermore, such vector particles may infect germline cells. Besides the high costs of such protocols, additional problems have been uncovered: 2, 3 
eg most recent data indicate that human cells cultivated with fetal
Correspondence: R Dornburg Received 23 June 1999; accepted 14 July 1999 bovine serum (present in almost all growth media) take up and process bovine proteins, and display bovine peptides on the cell surface evoking an immune response. Thus, gene transduced cells are cleared by the immune system.
The shortcomings and flaws associated with ex vivo protocols may be bypassed by a cell type-specific gene delivery system, which enables the injection of the gene delivery vehicle directly into the patient's blood stream or tissue of interest. The cell-type specificity of the retroviral particle is determined by the nature of the envelope protein, which mediates the binding of the virus to a receptor of the target cell. 4 Thus, experiments have been initiated in some laboratories to modify the retroviral envelope protein in order to alter the host range of the vector particle. [5] [6] [7] [8] [9] [10] Our laboratory provided proof of principle that retroviral vectors derived from spleen necrosis virus (SNV, an avian reticuloendotheliosis virus), which display the antigen binding site of an antibody (single chain antibodies, scAs, also termed scFvs) on the viral surface, enable a cell type-specific gene transfer into human cells. 6, [9] [10] [11] Infectivity was mediated by and specific for the scA. ScAs have been developed for E. coli expression to bypass the costly production of monoclonal antibodies in tissue culture or mice. 12, 13 They comprise the variable domains of both the heavy and light chain of an antibody molecule connected by a peptide bridge. This peptide bridge is encoded in a spacer region inserted between the coding regions of the two variable domains (Figure 1) .
Recently, we performed a series of experiments with vector particles that display a single chain antibody against the human Her2neu protein. 10 Her2neu belongs to the tyrosine-kinase receptor family and is expressed on many cell types (eg HeLa or COLO320DM cells) and over-expressed in 25% of breast tumors.
14 It is not expressed in A431 cells. We found that COLO320DM cells could be efficiently infected in vitro (titers above 10 5 cfu/ml). No infectivity was observed in A431 cells. 10 However, A431 cells could be infected with vector particles that displayed an scA against the transferrin receptor. Thus, the lack of infectivity in A431 cells of particles displaying anti-Her2neu scAs resulted from the lack of a Her2neu receptor on the cell surface. 10 Moreover, inhibition assays with monoclonal antibodies or soluble Her2neu showed that the infectivity in COLO320DM cells was mediated by the antibody moiety of the vector particles. Her2neu is expressed on most human cells and tissues. Thus, targeting Her2neu-positive cells has probably no clinical value for cell type-specific gene delivery in humans to cure a particular disease. However, the Her2neu targeting system was very useful to test proof of principle of in vivo cell type-specific gene delivery, since it has been very well characterized in vitro. 10 
Results
To study the transfer of genes with vectors displaying the anti-Her2neu scA into distinctive target cells in vivo, we have developed a small animal model system using severe combined immunodeficient (SCID) mice. SCID mice are deficient in functional B and T lymphocytes. Thus, they are unable to reject allogeneic organ grafts. SCID mice have been used extensively to study human leukemia and other malignancies, and for modeling human retroviral pathogenesis including anti-viral gene therapy. [15] [16] [17] [18] [19] [20] Thus, SCID mice appeared also to be ideal candidates to initiate experiments to get first insights into the feasibility of cell type-specific gene transfer in vivo. Moreover, reticuloendotheliosis viruses (REV) are not infectious and/or pathogenic in man or rodents. Taylor and Olson 21 have shown that mice injected with the highly pathogenic REV-T strain neither developed any disease symptoms nor any other signs of a viral infection. Using standard SNV vectors and packaging lines (vector virus harvested from DSH-cxl cells), we did not observe any infectivity in mouse, other rodent, or human cells (Refs 6, 7, 9, 10 and unpublished data). Similar observations have been made recently in other laboratories. Thus, the mouse model closely mimics a possible future application of SNV-derived targeting vectors in man and was very suitable to set up proof of principle experiments to show that a cell type-specific gene delivery can be obtained in vivo.
SNV particles and complement inactivation
It has been known for several decades that retroviral particles are rapidly inactivated in vivo by complement, if the virus particle has been produced by cells of a heterologous species. For example, murine retroviruses produced from mouse cells are resistant to mouse serum. However, they are rapidly inactivated by human serum. [22] [23] [24] Recently, it has been shown that this generally applies to retroviral vectors produced from mouse or mink cells. 25, 26 It has been postulated that natural antibodies bind to cellular proteins, which are coincorporated into the viral particle or to species-specific carbohydrate side chains of the envelope protein. Such antibody binding leads to the complement inactivation of the viral vector particle within a few minutes. Alternatively, complement inactivation may also be antibodyindependent.
Little is known regarding complement inactivation of SNV produced from dog D17 cells by mouse serum. Thus, we first investigated whether standard and targeting vectors of SNV were inactivated by mouse complement. A series of experiments with various vector preparations was performed. Vector harvested from confluent tissue culture helper cells was incubated with different amounts of fresh mouse serum or heat inactivated mouse serum for various periods of time. We did not observe any significant inactivation of SNV particles, neither with fresh nor with heat inactivated serum, even if the vector solution was mixed with serum 1:1 and incubated up to 1 h (data not shown). Thus, SCID mouse serum appears not to inactivate SNV vectors produced from dog cells. Although intraperitoneal injection of vectors does not expose the virus particle directly to comp-lement, the finding that SNV particles are resistant to mouse serum indicated that they may survive long enough to locate and infect their actual target cells in vivo.
In vivo experimental protocol
To obtain a first insight into whether retroviral targeting vectors can infect cells in vivo, a series of simple SCID mice experiments were performed. All experiments described below were performed using the following experimental protocol (see also Figure 2 ). 10 6 antibiotic resistant cells (human target or non-target cells or dog D17 cells) were injected into the peritoneum of SCID mice. After 12 h and again after 24 h, 10 6 infectious virus particles transducing the bacterial beta-galactosidase gene were injected. After another 24 h, the mice were killed and cells were extracted from the peritoneum by flushing the cavity with a 0.2% trypsin solution. This procedure not only recovers human cells, which had attached to mouse tissues but also removes millions of murine cells (in particular epithelial cells). All cells were placed in tissue culture with growth medium specific for the cells to be selected. Since human (or dog D17) cells were antibiotic resistant, they could be selected easily by adding the corresponding antibiotic to the tissue culture medium. For example, when COLO320 DM cells were to be recovered, cells isolated from the peritoneum were placed in tissue culture with RPMI medium containing 10% FBS and puromycin (750 ng/ml). In all experiments, we found that only up to a few hundred colonies of human cells could be recovered per mouse. Thus, more than 99% of the injected cells were cleared within 48 h after injection by the animal. After 7 to 10 days in tissue culture (when most of the mouse cells had died and human cells grew out as colonies), cells were stained with X-gal, as described. 7, 27 Blue cells indicate successful infection in vivo.
In vivo experiments
As outlined above, we found that mouse cells could not be infected by wild-type SNV vector particles in vitro. To corroborate this finding in vivo, we first injected 10 6 virus particles displaying wild-type envelope, or in another experiment, 10 6 infectious vector particles displaying anti-Her2neu scAs, into the peritoneum of mice without prior injection of human or dog cells. Mouse cells were recovered as described above and stained after 1 day in tissue culture (without antibiotic selection). No infected mouse cells were detected. These data confirm that mouse cells are not infected by wild-type SNV or SNV vectors that display anti-Her2neu scAs (Figure 3a and Table 1 ).
To test whether wild-type SNV infects D17 cells or human cells in vivo, in another set of experiments, a mixture of 10 6 D17 + 10 6 COLO320DM cells or a mixture of 10 6 D17 cells + 10 6 HeLA cells were injected, followed by the injection of 2 × 10 6 infectious vectors containing solely the wild-type SNV envelope. Cells were recovered as described above and placed under antibiotic selection. It was demonstrated that wild-type SNV infected dog D17 cells very efficiently in vivo: up to 10% of the D17 cells recovered were infected. However, no infected human cells could be detected (Figure 3b and c, Table 1 ). These data indicate the SNV remained highly infectious in vivo. Furthermore, these data also demonstrated that no non-specific infections of the human cells occurred in the animal.
The transduction of genes into human cells with SNV targeting vectors was tested in different experiments as described above. First, human COLO320DM or A431 cells were injected into SCID mice. A431 cells do not express Her2neu and could not be infected with anti-Her2neu targeting vectors in vitro. 10 Our data show that COLO320DM cells were infected in vivo (Figure 3e and Table 1 ). However, A431 cells were not infected ( Figure 3d and Table 1 ). Moreover, when a mixture of COLO320DM and A431 cells were injected together, infection was only observed in COLO320DM cells, but not in A431 cells (Figure 3h and i and Table 1 ). (In these experiments, 1 × 10 6 COLO320DM cells were mixed with 1 × 10 6 A431 cells and injected into the animals. The COL-O320DM cells were puromycin resistant, A431 cells were resistant to hygromycin B. After vector injection and recovery of the cells, the cells were split in half and put in tissue culture: one half was subjected to hygromycin selection (selection for A431 cells), the other half of the plates were subjected to puromycin selection (only COL-O320DM cells survive)). Similar observations were made when in vivo infectivity was tested with a mixture of HeLa and A431 cells: only the HeLa cells were infected, but not the A431 cells (Table 1) .
In control experiments, COLO320DM cells or mixtures of COLO320DM plus A431 cells or HeLa plus A431 cells were injected into SCID mice, followed by the injection of 10 6 infectious virus particles containing wild-type envelope only. No infectivity was observed (Table 1) 
subjected in vivo to SNV-derived vectors displaying wild-type envelope (a-c) or targeting envelopes (d-i) and transducing the bacterial ␤-galactosidase gene. (a) Primary mouse cells; (b) COLO320DM cells; (c) a mixture of human HeLa (top left) and dog D17 cells; (d) A431 cells; (e) COLO320DM cells; (f and g) A431 cells (f) and COLO320DM cells (g) were mixed, infected in vitro, followed by different antibiotic selection and X-gal staining; (h and i) A431 cells and COLO320DM cells were mixed, injected into mice, followed by the injection of vectors displaying anti-Her2neu scAs. Recovered cells were split in half and selected for hygromycin (A431 cells, h) or puromycin (COLO320DM cells, i). (i) Colonies of COLO320DM cells demonstrating the stable integration of the transgene into the genome of the target cells.
After approximately 10 days, the cells were stained with X-gal as described above. We found that about 10 to 20% of the COLO320DM cells were infected. No infected A431 cells were detected (Figure 3f and g ). Thus, targeting vectors showed target cell-specificity in vivo similar to that observed in vitro. The efficiency of infection in vivo was about 5% of that observed in vitro.
Discussion
In the past decade, many efforts have been made to develop cell type-specific gene delivery tools for future in vivo gene transfer applications to bypass cumbersome and expensive ex vivo gene therapy protocols. We have shown that SNV-derived retroviral vector particles that 6 infectious vector virus particles transducing the bacterial ␤-galactosidase (lacZ) gene were injected. At day 3, mice were killed and the injected cells were recovered by flushing the peritoneum with a 0.2% trypsin solution. The recovered cells were put in tissue culture in the presence of antibiotics to select for viable injected cells. After another 7 to 10 days, cells were stained with X-gal. Blue cells indicate infected cells, eg lacZ expression from the retroviral vector genome (see also Figure 3 ). All experiments were repeated twice with two mice each and similar results were obtained in all experiments. NICD, no infected cells detected; ND, not done.
display the antigen binding site of an antibody on the viral surface enable a cell type-specific gene delivery into human cells in vitro, when the receptor recognized by the scA was present on the cell surface. To test whether such particles would also be able to deliver genes into distinct target cells in vivo, we used SCID mice as a model system. The SCID mouse model system mimics a future gene transfer application in humans for the following reason: wild-type SNV does not infect human or mouse cells in vitro. Consequently, vectors without a specific targeting ligand were also expected not to infect such cells in vivo.
Thus, it could be tested whether retroviral vector particles specific for a particular cell type could find and infect the correct target cell in vivo. Although the Her2neu system has little potential for therapeutic applications in humans, 10 this system and the use of a marker gene were very useful for first in vivo gene delivery experiments to demonstrate the feasibility of this approach.
Here, we show that SNV-derived retroviral vector particles behaved in vivo as they did in vitro: mouse cells were not infected in vivo at detectable levels by vector particles displaying either wild-type envelope or antiHer2neu scAs on the viral surface. However, an efficient gene transfer into Her2neu-positive human cells could be obtained with retroviral vectors, which display the antigen binding site of an antibody against Her2neu. Moreover, such targeting vectors only infected human Her2-neu-positive cells, when a mixture of Her2neu-positive and -negative human cells was injected into the mouse.
In summary, to our knowledge, this is the first report that shows proof of principle of cell type-specific gene delivery in vivo. Although the efficiency of the gene transfer into human target cells was below 5%, it has to be considered that relatively low titer vector virus solutions were injected, because the gene delivery system applied here had not been optimized for high vector virus titers at this time. However, the data presented in this study indicate that retroviral targeting vectors are feasible for in vivo application. Thus, they may also be used in the future for a large variety of human gene therapy applications, in which cell type-specific gene delivery will be essential, eg the introduction of therapeutic anti-HIV-1 genes into human hematopoietic stem cells. 28 Previously, we have demonstrated that the SNV vector system is in particular very well suited to introduce genes into cells of the hematopoietic system. 10 Thus, our future aims will be focussed on the development of new vector systems displaying different scAs suitable to target cells of the hematopoietic system and to test the effect of a therapeutic gene. However, further optimization will still be necessary to bring this technology into the clinic.
Materials and methods
Cells D17 cells, a dog osteosarcoma cell line, A413, COLO-320DM cells, and HeLa cells were grown as described previously. 10 These human or dog D17 cells were made antibiotic resistant by transfecting plasmids expressing antibiotic resistance genes using the polybrene/DMSO transfection protocol, 29 followed by antibiotic selection. All A431 cells used in this study were hygromycin resistant; COLO320DM, D17, or HeLa cells were made puromycin resistant.
Intraperitoneal injection of cells
Before injection into the animal, the adherent cells were treated with a 0.2% trypsin solution to get them off the tissue culture plates and neutralized with growth medium as described. The number of cells was determined. The cell solution was subjected to centrifugation at 200 g in a clinical centrifuge for 5 min at room temperature. The cell pellet was suspended in various amounts of fresh growth medium to achieve a concentration of 10 6 cells/ml medium. 1 ml of this cell solution was injected i.p. into a SCID mouse.
Helper cells and vector preparations
The preparation of stable helper cells producing retroviral vectors displaying anti-Her2neu scAs or wild-type envelope proteins has been described in detail recently. 6, 9, 10, 30 The preparation of vector virus particle solutions used for in vivo infection was identical to those described in detail recently. 9, 10 
